Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

Abstract The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of mul...

Full description

Bibliographic Details
Main Authors: Hua Qin, Andong Zhao
Format: Article
Language:English
Published: SpringerOpen 2020-06-01
Series:Protein & Cell
Subjects:
mesenchymal stem cells
cell therapy
acute respiratory distress syndrome
SARS-CoV-2
COVID-19
pneumonia
Online Access:https://doi.org/10.1007/s13238-020-00738-2

Internet

https://doi.org/10.1007/s13238-020-00738-2

Similar Items